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Epidermal necrolysis (EN), including Stevens-Johnson syndrome (SJS) (detachment involving <10% 
body surface area [BSA]), toxic epidermal necrolysis (TEN, ≥30% BSA), and overlap syndrome (10-
29% BSA) is characterized by a widespread apoptotic destruction of the epidermis and mucous 
membranes.
1
 Ocular involvement is observed in 75% of patients at the acute phase.
2
 Severity may be 
classified according to Power’s criteria (mild, moderate or severe involvement).3 Ocular sequelae 
(OS) may result in permanent visual impairment and require prolonged follow-up.
4  
 
Scleral lenses (SLs) are large-diameter gas-permeable contact lenses designed to cover the corneal 
surface and protect the cornea against tear evaporation and mechanical trauma of the pathological 
eyelids while improving visual acuity. SLs have been found effective in improving the comfort of 
patients with the most disabling OS (marked dryness, symblepharons, persistent inflammation or loss 
of visual acuity).
5
  
 
This study aimed to determine the risk factors for disabling OS and to identify associated sequelae. 
We retrospectively included all EN patients admitted to our reference center at the acute phase 
between 2005 and 2017 and followed for at least 6 months. The diagnosis was according to 
previously published clinical and histological criteria.
1 
We defined disabling OS by the need to wear 
SLs. Indeed, in our routine practice, according to the dermatologist’s and local ophthalmologist’s 
decision, patients considered to have the most disabling OS were referred to the same ophthalmologist 
expert in the field of EN (AD) for SLs. We collected the following data from medical charts: 1) data 
on the acute phase: age, sex, Fitzpatrick skin type (I-IV vs V-VI), maximal skin detachment, highest 
SCORTEN 
6
 during the first 5 days, number of mucous membranes affected (≤  or > 3), transfer to an 
intensive care unit, initial ocular involvement according to Power’s criteria3 and 2) associated 
sequelae: cutaneous, nail, and psychiatric sequelae during follow-up.  
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Demographic and clinical characteristics were expressed as mean (SD) or number (%). Differences 
between patients with and without SLs were investigated by univariate logistic regression, estimating 
odds ratios (ORs) and 95% confidence intervals (CIs). The OR significance was determined by Wald, 
chi-square or Fisher’s exact test as appropriate, with P < .05 considered statistically significant. 
Patients gave consent for the use of anonymized data and the database was declared to the 
Commission Nationale Informatique et Libertés (no. 20190327153039).  
 
Among 205 consecutive patients referred during the study period, 177 (99 females; mean [SD] age 46 
[20] years) were included; 26 (15%) had an indication for SLs and were compared to 151 without SLs 
(Table). The median time between the acute phase and the first SL consultation (n=20) was 1 year (6 
months-6 years).  
 
During the acute phase, the following were higher or more frequent in patients with than without SLs: 
mean [SD] BSA involved (39% [28%] vs 21% [22%], p = .0009), mean SCORTEN (2.19 [1] vs 1.58 
[1], p = .011), extensive mucosal involvement (58% vs 35%, p = .03), and severe Power stage (77% 
vs 9%, p < .0001). However, we found no association between OS and sex, age, Fitzpatrick skin type, 
transfer to an intensive care unit or treatment with cyclosporine.  
 
Similarly, during follow-up, nail sequelae were more frequent in patients with than without SLs (54% 
vs 24%, p = .002), as were psychiatric disorders (58% vs 25%, p= .001). We found no association 
between OS and pigmentation sequelae.   
 
Overall, 15% of our patients warranted SLs. At the acute phase, EN was more severe with than 
without SLs: higher percentage of detached skin, more extensive mucosal involvement, higher 
SCORTEN, and more severe eye damage. In our study, phototype was not associated with increased 
risk of development of disabling OS. However, we recently showed that among patients requiring 
SLs, Fitzpatrick skin type V-VI was associated with more severe ophthalmological involvement (loss 
of visual acuity, symblepharons, trichiasis, corneal ulcerations).
7 
Thus, rigorous ophthalmologic care 
is needed at the acute disease phase, but consensual guidelines are lacking.
4
 Encouraging preliminary 
results have been obtained for amniotic membrane transplantation.
8  
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Our study emphasizes the significant association between disabling OS and other sequelae that impair 
quality of life (nail and psychiatric sequelae).  
 
 
The limitations of our study include a probable underestimation of the number of patients requiring 
SL because not all patents were necessarily referred to the specialized consultation. As well, details 
on the severity of psychiatric sequelae were lacking because of the retrospective design. 
 
The initial disease severity is the main risk factor for disabling OS. Initial close ophthalmologic 
screening and follow-up is warranted. Consensus is needed for the best ophthalmological treatment at 
the acute phase.  
  
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
References 
1. Duong TA, Valeyrie-Allanore L, Wolkenstein P, Chosidow O. Severe cutaneous adverse 
reactions to drugs. Lancet. 2017;390:1996-2011. 
2. Gueudry J, Roujeau JC, Binaghi M, Soubrane G, Muraine M. Risk factors for the development of 
ocular complications of Stevens-Johnson syndrome and toxic epidermal necrolysis. Arch 
Dermatol 2009;145:157-62. 
3. Power WJ, Ghoraishi M, Merayo-L, loves J, Neves RA, Foster CS. Analysis of the acute 
ophthalmic manifestations of the erythema multiforme/Stevens-Johnson syndrome/toxic 
epidermal necrolysis disease spectrum. Ophthalmology. 1995;102:1669-1676. 
4. Ingen-Housz-Oro S, Duong TA, Bensaid B et al. Epidermal necrolysis French national diagnosis 
and care protocol (PNDS; protocole national de diagnostic et de soins). Orphanet J Rare Dis. 
2018;13:56. doi:10.1186/s13023-018-0793-7. 
5. Tougeron-Brousseau B, Delcampe A, Gueudry J et al. Vision-related function after scleral lens 
fitting in ocular complications of Stevens-Johnson syndrome and toxic epidermal necrolysis. Am J 
Ophthalmol. 2009;148:852-9.  
6. Guégan S, Bastuji-Garin S, Poszepczynska-Guigné E, Roujeau JC, Revuz J. Performance 
of the SCORTEN during the first five days of hospitalization to predict the prognosis of 
epidermal necrolysis. J Invest Dermatol. 2006 Feb;126(2):272-6. 
7. D. Thorel, A. Delcampe, S. Ingen-Housz-Oro et al. Skin phototype may be a risk foctor 
for ocular complications of Stevens-Johnson and toxic epidermal necrolysis.  Br J 
Dermatol. 2019 Jan 11. doi: 10.1111/bjd.17627 
8.   Kobayashi A, Yoshita T, Sugiyama K et al. Amniotic membrane transplantation in acute phase of 
toxic epidermal necrolysis with severe corneal involvement. Ophthalmology. 2006;113:126-132. 
 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
Table: Comparison of risk factors at the acute phase of epidermal necrolysis and associated sequelae between patients with and without scleral 
lenses. 
Variables Total 
n=177 
Scleral lenses  
n=26 
No scleral lenses  
n=151 
OR [95% CI] p-value 
Demographic characteristics      
Female sex, n (%) 99 (56) 18 (69) 81 (54) 1.94 [0.79-4.78] .14 
Age, mean (SD) 92 (52) 46 (20) 46 (19) 1 [0.98-1.02] .99 
Phototype V-VI, n (%) 61 (34) 10 (38) 51 (34) 1.23 [0.52-2.90] .64 
Stevens-Johnson syndrome, n (%) 61 (34) 4 (15) 57 (38) 3.34 [1.07-10.37] .03 
Overlap syndrome or toxic epidermal necrolysis, n (%) 116 (66) 22 (85) 94 (62) 
Maximum skin detachment (BSA), mean (SD) 28% (27)  39% (28) 21% (22)  1.02 [1.01-1.04] .0009 
Maximum SCORTEN, mean (SD) 1.86 (1.24) 2.19 (1) 1.58 (1) 1.67 [1.12-2.47] .011 
Number of affected mucous membranes >3, n (%) 68 (38) 15 (58) 53 (35) 2.52 [1.07-5.96] .03 
Initial ocular involvement according Power criteria*, n 
(%) 
     
  No or mild involvement 81 (46) 2 (8) 
$
 110 (73) 68.1 [9.76-733.51] <.0001 
  Moderate involvement 32 (18) 4 (15) 
$$
 28 (19) 
  Severe involvement 33 (19) 20 (77) 
$$$
 13 (9) 
Transfer to ICU, n (%) 36 (20) 7 (27) 29 (19) 1.54 [0.59-4.05] .37 
Treatment with cyclosporine, n (%)** 69 (40) 13 (50) 56 (38) 1.60 [0.64-4.05] .26 
BSA, body surface area; SCORTEN, severity-of-illness score for TEN; ICU, intensive care unit; * Power criteria: mild involvement (eyelid edema, and/or mild conjunctival injection, and/or 
chemosis only), moderate involvement (membranous conjunctivitis, and/or corneal epithelial defects, more than 30% healing with medical treatment, and/or corneal ulceration, and/or corneal 
infiltrates ) or severe involvement (symblepharon formation, and/or nonhealing corneal epithelial defects, and/or visual loss, and/or conjunctival fornix foreshortening); **missing data n=5; $: 
mild conjunctival injection; $$: corneal ulceration; $$$: symblepharon formation (n=18) and non-healing corneal epithelial defects (n=2)  
